ArticleInfection and drug resistance2011
Update on the optimal use of voriconazole for invasive fungal infections.
Article in Infection and drug resistance, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 83 citations in OpenAlex.
- Empirical voriconazole therapy for febrile neutropenic patients with hematological disorders: a prospective multicenter trial in Japan.Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy · 2013Trial
- Two-stage revision combined with anti-infective therapy for mixed fungal and bacterial knee periprosthetic joint infection: a case report and literature review.BMC musculoskeletal disorders · 2026Review
- Pathogenesis and Triazole Resistance inInfection and drug resistance · 2026Review
- Current Updates on Pathogenesis, Systemic Therapy, and Treatment of Invasive Fungal Infections.Current drug targets · 2025Review
- The epidemiological characteristics of invasive pulmonary aspergillosis and risk factors for treatment failure: a retrospective study.BMC pulmonary medicine · 2024Article
- Changing Spectrum of Invasive Fungal Infections of the Anterior Skull Base.Journal of neurological surgery. Part B, Skull base · 2024Article
- Efficacy and safety of caspofungin for the treatment of invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease.The Journal of international medical research · 2024Article
- Phaeohyphomycosis caused byMycology · 2024Article
- Article
- Article
- Article
- A Guidance for Concomitant Drug Reconciliation Prior to Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults.Frontiers in pediatrics · 2021Article
- Association of Voriconazole Trough Plasma Concentration with Efficacy and Incidence of Hepatotoxicity in Iranian Patients with Hematological Malignancies.Iranian journal of pharmaceutical research : IJPR · 2021Article
- Characterization of Therapeutic Drug Monitoring Practices of Voriconazole and Posaconazole at a Pediatric Hospital.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2021Article
- Tryptophol Coating Reduces Catheter-Related Cerebral and Pulmonary Infections byInfection and drug resistance · 2020Article
- Ocular Inserts of Voriconazole-Loaded Proniosomal Gels: Formulation, Evaluation and Microbiological Studies.International journal of nanomedicine · 2020Article
- Voriconazole enhances UV-induced DNA damage by inhibiting catalase and promoting oxidative stress.Experimental dermatology · 2020Article
- In vitro antifungal activity of a novel topical triazole PC945 against emerging yeast Candida auris.The Journal of antimicrobial chemotherapy · 2019Article
- Subcutaneous Fungal Infection Caused by a Non-sporulating Strain of Corynespora cassiicola Successfully Treated with Terbinafine.Mycopathologia · 2019Article
- Insight into the Significance of Aspergillus fumigatus cyp51A Polymorphisms.Antimicrobial agents and chemotherapy · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Voriconazole is an extended-spectrum triazole with excellent bioavailability that has now become the treatment of choice for aspergillosis. It has a unique side effect profile compared with other azoles, as well as a number of clinically important drug-drug interactions. These factors, along with a correlation between increased serum levels and improved outcomes, have prompted an interest in therapeutic drug monitoring of this agent. The pharmacology and clinical outcomes data of voriconazole are presented in this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.